Cargando…
An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids
Patient-derived tumor organoids (PDOs) represent a promising preclinical cancer model that better replicates disease, compared with traditional cell culture models. We have established PDOs from various human tumors to accurately and efficiently recapitulate the tissue architecture and function. Mol...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562414/ https://www.ncbi.nlm.nih.gov/pubmed/31137590 http://dx.doi.org/10.3390/cells8050481 |
_version_ | 1783426294493478912 |
---|---|
author | Takahashi, Nobuhiko Hoshi, Hirotaka Higa, Arisa Hiyama, Gen Tamura, Hirosumi Ogawa, Mayu Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki |
author_facet | Takahashi, Nobuhiko Hoshi, Hirotaka Higa, Arisa Hiyama, Gen Tamura, Hirosumi Ogawa, Mayu Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki |
author_sort | Takahashi, Nobuhiko |
collection | PubMed |
description | Patient-derived tumor organoids (PDOs) represent a promising preclinical cancer model that better replicates disease, compared with traditional cell culture models. We have established PDOs from various human tumors to accurately and efficiently recapitulate the tissue architecture and function. Molecular targeted therapies with remarkable efficacy are currently in use against various tumors. Thus, there is a need for in vitro functional-potency assays that can be used to test the efficacy of molecular targeted drugs and model complex interactions between immune cells and tumor cells to evaluate the potential for cancer immunotherapy. This study represents an in vitro evaluation of different classes of molecular targeted drugs, including small-molecule inhibitors, monoclonal antibodies, and an antibody-drug conjugate, using lung PDOs. We evaluated epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) inhibitors using a suitable high-throughput assay system. Next, the antibody-dependent cellular cytotoxicity (ADCC) activity of an anti-HER2 monoclonal antibody was evaluated to visualize the interactions of immune cells with PDOs during ADCC responses. Moreover, an evaluation system was developed for the immune checkpoint inhibitors, nivolumab and pembrolizumab, using PDOs. Our results demonstrate that the in vitro assay systems using PDOs were suitable for evaluating molecular targeted drugs under conditions that better reflect pathological conditions. |
format | Online Article Text |
id | pubmed-6562414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65624142019-06-17 An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids Takahashi, Nobuhiko Hoshi, Hirotaka Higa, Arisa Hiyama, Gen Tamura, Hirosumi Ogawa, Mayu Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki Cells Article Patient-derived tumor organoids (PDOs) represent a promising preclinical cancer model that better replicates disease, compared with traditional cell culture models. We have established PDOs from various human tumors to accurately and efficiently recapitulate the tissue architecture and function. Molecular targeted therapies with remarkable efficacy are currently in use against various tumors. Thus, there is a need for in vitro functional-potency assays that can be used to test the efficacy of molecular targeted drugs and model complex interactions between immune cells and tumor cells to evaluate the potential for cancer immunotherapy. This study represents an in vitro evaluation of different classes of molecular targeted drugs, including small-molecule inhibitors, monoclonal antibodies, and an antibody-drug conjugate, using lung PDOs. We evaluated epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) inhibitors using a suitable high-throughput assay system. Next, the antibody-dependent cellular cytotoxicity (ADCC) activity of an anti-HER2 monoclonal antibody was evaluated to visualize the interactions of immune cells with PDOs during ADCC responses. Moreover, an evaluation system was developed for the immune checkpoint inhibitors, nivolumab and pembrolizumab, using PDOs. Our results demonstrate that the in vitro assay systems using PDOs were suitable for evaluating molecular targeted drugs under conditions that better reflect pathological conditions. MDPI 2019-05-20 /pmc/articles/PMC6562414/ /pubmed/31137590 http://dx.doi.org/10.3390/cells8050481 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Takahashi, Nobuhiko Hoshi, Hirotaka Higa, Arisa Hiyama, Gen Tamura, Hirosumi Ogawa, Mayu Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids |
title | An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids |
title_full | An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids |
title_fullStr | An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids |
title_full_unstemmed | An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids |
title_short | An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids |
title_sort | in vitro system for evaluating molecular targeted drugs using lung patient-derived tumor organoids |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562414/ https://www.ncbi.nlm.nih.gov/pubmed/31137590 http://dx.doi.org/10.3390/cells8050481 |
work_keys_str_mv | AT takahashinobuhiko aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT hoshihirotaka aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT higaarisa aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT hiyamagen aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT tamurahirosumi aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT ogawamayu aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT takagikosuke aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT godakazuhito aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT okabenaoyuki aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT mutosatoshi aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT suzukihiroyuki aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT shimomurakenju aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT watanabeshinya aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT takagimotoki aninvitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT takahashinobuhiko invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT hoshihirotaka invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT higaarisa invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT hiyamagen invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT tamurahirosumi invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT ogawamayu invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT takagikosuke invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT godakazuhito invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT okabenaoyuki invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT mutosatoshi invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT suzukihiroyuki invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT shimomurakenju invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT watanabeshinya invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids AT takagimotoki invitrosystemforevaluatingmoleculartargeteddrugsusinglungpatientderivedtumororganoids |